References
- Akhter E, Burlingame RW, Seaman AL, et al. (2011). Anti-C1q antibodies have higher correlation with flares of lupus nephritis than other serum markers. Lupus, 20, 1267–74
- Bachy E, Besson C, Suarez F, Hermine O. (2010). Hepatitis C virus infection and lymphoma. Mediterr J Hematol Infect Dis, 2, e2010004
- Barsoum RS. (2007). Hepatitis C virus: From entry to renal injury–facts and potentials. Nephrol Dial Transplant, 22, 1840–8
- Bassyouni IH, Gamal S, Talaat RM, Siam I. (2014). Autoantibodies against complement C1q in patients with Behcet’s disease: Association with vascular involvement. Mod Rheumatol, 24, 316--20
- Bianchi FB, Muratori P, Granito A, et al. (2007). Hepatitis C and autoreactivity. Dig Liver Dis, 39 Suppl 1, S22–4
- De Re V, Caggiari L, Garziera M, et al. (2012). Molecular signature in HCV-positive lymphomas. Clin Dev Immunol, 2012, 623465
- El-Hewala A, Nageeb GS, El-shahawy EE, et al. (2011). Anti-C1q and anti-dsDNA antibodies in systemic lupus erythematosus: Relationship with disease activity and renal involvement in Sharkia governorate, Egypt. Egypt Rheumatol, 33, 203–8
- Esmat S, Omran D, Sleem GA, Rashed L. (2012). Serum mannan-binding lectin in egyptian patients with chronic hepatitis C: Its relation to disease progression and response to treatment. Hepat Mon, 12, 259–64
- Himoto T, Masaki T. (2012). Extrahepatic manifestations and autoantibodies in patients with hepatitis C virus infection. Clin Dev Immunol, 2012, 871401
- Hu SY, Jia XY, Yang XW, et al. (2013). Glomerular C1q deposition and serum anti-C1q antibodies in anti-glomerular basement membrane disease. BMC Immunol, 21, 14–42
- Indolfi G, Bartolini E, Olivito B, et al. (2012). Autoimmunity and extrahepatic manifestations in treatment-naïve children with chronic hepatitis C virus infection. Clin Dev Immunol, 2012, 785627
- Jacobson IM, Cacoub P, Dal Maso L, et al. (2010). Manifestations of chronic hepatitis C virus infection beyond the liver. Clin Gastroenterol Hepatol, 8, 1017–29
- Kallenberg CG. (2008). Anti-C1q autoantibodies. Autoimmun Rev, 7, 612–5
- Lauletta G, Russi S, Conteduca V, Sansonno L. (2012). Hepatitis C virus infection and mixed cryoglobulinemia. Clin Dev Immunol, 2012, 502156
- Lienesch DW, Sherman KE, Metzger A, Shen GQ. (2006). Anti-Clq antibodies in patients with chronic hepatitis C infection. Clin Exp Rheumatol, 24, 183–5
- Mahler M, van Schaarenburg RA, Trouw LA. (2013). Anti-C1q autoantibodies, novel tests, and clinical consequences. Front Immunol, 14, 117
- Morales JM, Kamar N, Rostaing L. (2012). Hepatitis C and renal disease: Epidemiology, diagnosis, pathogenesis and therapy. Contrib Nephrol, 176, 10–23
- Potlukova E, Kralikov P. (2008). Complement component C1q and Anti-C1q antibodies in theory and in clinical practice. Scand J Immunol, 67, 423–430
- Qin X, Gao B. (2006). The complement system in liver diseases. Cell Mol Immunol, 3, 333–40
- Ricklin D, Hajishengallis G, Yang K, Lambris JD. (2010). Complement: A key system for immune surveillance and homeostasis. Nat Immunol, 11, 785–97
- Saadoun D, Sadallah S, Trendelenburg M, et al. (2006). Anti-C1q antibodies in hepatitis C virus infection. Clin Exp Immunol, 145, 308–12
- Sarafidis PA, Ruilope LM. (2006). Insulin resistance, hyperinsulinemia, and renal injury: Mechanisms and implications. Am J Nephrol, 26, 232–44
- Sène D, Limal N, Ghillani-Dalbin P, et al. (2007). Hepatitis C virus-associated B-cell proliferation—The role of serum B lymphocyte stimulator (BLyS/BAFF). Rheumatology (Oxford), 46, 65–9
- Stoyanova V, Petrova S, Tchorbadjieva M, et al. (2011). New insight into the autoimmunogenicity of the complement protein C1q. Mol Immunol, 48, 678–82
- Sun J, Lin Z, Feng J, et al. (2008). BAFF-targeting therapy, a promising strategy for treating autoimmune diseases. Eur J Pharmacol, 597, 1–5
- Trouw LA, Daha MR. (2011). Role of complement in innate immunity and host defense. Immunol Lett, 138, 35–7
- Trouw LA, Groeneveld TW, Seelen MA, et al. (2004). Anti-C1q autoantibodies deposit in glomeruli are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest, 114, 679–88
- Vergani D, Mieli-Vergani G. (2013). Autoimmune manifestations in viral hepatitis. Semin Immunopathol, 35, 73–85
- Yang XW, Tan Y, Yu F, Zhao MH. (2012). Combination of anti-C1q and anti-dsDNA antibodies is associated with higher renal disease activity and predicts renal prognosis of patients with lupus nephritis. Nephrol Dial Transplant, 27, 3552–9
- Yao ZQ, Ni L, Zhang Y, et al. (2011). Differential regulation of T and B lymphocytes by PD-1 and SOCS-1 signaling in hepatitis C virus-associated non-Hodgkin’s lymphoma. Immunol Invest, 40, 243–64
- Zaki Mel S, Saudy N, El Diasty A. (2010). Study of nitric oxide in patients with chronic hepatitis C genotype 4: Relationship to viremia and response to antiviral therapy. Immunol Invest, 39, 598–610
- Zhang CQ, Ren L, Gao F, et al. (2011). Anti-C1q antibodies are associated with systemic lupus erythematosus disease activity and lupus nephritis in northeast of China. Clin Rheumatol, 30, 967–73